MFLUSIVA and the new melanoma results show why we shouldn’t allow the controversies of the pandemic to dictate the future of mRNA. The technology should be judged by what it delivers. And it’s only beginning to show us what it can do.
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it.
Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard flu shot at preventing lab-confirmed influenza.
That’s especially welcome news after one of the worst flu seasons in years. It’s also arriving at a strange moment for the technology behind it.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
The first mRNA flu vaccine may be just the beginning
Sally C. Pipes
MFLUSIVA and the new melanoma results show why we shouldn’t allow the controversies of the pandemic to dictate the future of mRNA. The technology should be judged by what it delivers. And it’s only beginning to show us what it can do.
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it.
Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard flu shot at preventing lab-confirmed influenza.
That’s especially welcome news after one of the worst flu seasons in years. It’s also arriving at a strange moment for the technology behind it.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.